Results 241 to 250 of about 2,714,339 (309)
Some of the next articles are maybe not open access.

A metalloproteinase inhibitor as an inhibitor of neovascularization

Journal of Cellular Biochemistry, 1991
AbstractMetalloproteinases and their endogenous inhibitors are key components of an enzyme system which is important in a number of fundamental biochemical and cellular processes. Our recent work has focused on the role of a particular metalloproteinase, collagenase, and the role of an endogenous inhibitor of this enzyme in the control of ...
M A, Moses, R, Langer
openaire   +2 more sources

Renin Inhibitors

Pharmaceutical Research, 1987
Since the early 1980s, an intensive effort has been focused on the development of orally effective and long-acting inhibitors of renin. During this time, in vitro potency has increased greatly, with several transition-state inhibitor designs yielding inhibitors with subnanomolar IC50 values.
openaire   +3 more sources

Farnesyltransferase inhibitors versus Ras inhibitors

Current Opinion in Chemical Biology, 1997
Over the past few years, the idea that farnesyl-protein transferase (FPTase) inhibitors might be effective antiproliferative/antitumor agents has been realized in studies of cultured cells and in rodent models of cancer. Most of the studies with FPTase inhibitors have focused on inhibiting the growth of ras-transformed cells in vitro or the growth of ...
J B, Gibbs   +6 more
openaire   +2 more sources

Aromatase inhibitors ? mechanisms of steroidal inhibitors

Breast Cancer Research and Treatment, 1994
Inhibition of aromatase has been an attractive approach for examining the roles of estrogen biosynthesis in various physiological or pathological processes. Effective aromatase inhibitors can serve as potential therapeutic agents for controlling estrogen-dependent diseases such as hormone-dependent breast cancer.
openaire   +2 more sources

Clinical Development of BRAF plus MEK Inhibitor Combinations

Trends in Cancer, 2020
John M Kirkwood   +2 more
exaly  

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

Annals of Oncology, 2017
Pier Luigi Zinzani   +2 more
exaly  

Home - About - Disclaimer - Privacy